Sanofi (NASDAQ:SNY) Shares Purchased by Foyston Gordon & Payne Inc

Foyston Gordon & Payne Inc grew its position in Sanofi (NASDAQ:SNY) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,036 shares of the company’s stock after acquiring an additional 252 shares during the quarter. Foyston Gordon & Payne Inc’s holdings in Sanofi were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in SNY. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Sanofi during the fourth quarter worth about $436,000. Park Avenue Securities LLC increased its holdings in shares of Sanofi by 14.3% in the 4th quarter. Park Avenue Securities LLC now owns 68,982 shares of the company’s stock worth $3,327,000 after acquiring an additional 8,615 shares during the period. Van ECK Associates Corp lifted its position in Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock valued at $31,965,000 after purchasing an additional 101,726 shares during the last quarter. Finally, Sound Income Strategies LLC increased its stake in shares of Sanofi by 156,520.9% in the fourth quarter. Sound Income Strategies LLC now owns 67,347 shares of the company’s stock valued at $3,248,000 after purchasing an additional 67,304 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.33.

Sanofi Price Performance

NASDAQ:SNY opened at $49.98 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $54.22 and its 200 day moving average price is $52.00. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The firm has a market cap of $126.26 billion, a P/E ratio of 20.07, a PEG ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.78 EPS. As a group, sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a dividend yield of 3.1%. This is a boost from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi’s payout ratio is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.